ClinicalTrials.gg
CompletedNCT03889145Updated Mar 26, 2019

A Study to Evaluate the Drug-drug Interaction Between Telmisartan, Amlodipine and Hydrochlorothiazide

A Phase 1 interventional study of Telmisartan 80mg and Amlodipine10mg in Healthy, sponsored by IlDong Pharmaceutical Co Ltd. Completed. Open to male participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-03-26.

Sponsored by IlDong Pharmaceutical Co Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 5 years 3 months after the study started (first participant enrolled Dec 2013, registered Mar 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
20 Years to 55 Years
Sex
Male
01

Study summary

A randomized, open-label, single dose, 3-way crossover study to evaluate the drug-drugs interaction between Telmisartan, Amlodipine and Hydrochlorothiazide in healthy male volunteers

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

IlDong Pharmaceutical Co Ltd is the lead sponsor of 50 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male volunteers aged 20 to 55 years
  • Subjects who have 17.5 \~ 30.5 kg/m2 (BMI) and body weight that is more than 55kg
  • Subjects who have no congenital or chronic disease within the last 3 years and have no pathological symptoms or findings as a result of medical examination.
  • Suitable subject who is determined by laboratory tests such as hematology tests, blood chemistry, urinalysis test according to the characteristics of the drug and screening tests such as electrocardiography() test.
  • Subject who fully understand the clinical trials after in-depth explanation given prior to the clinical study, decided to join the clinical trials by their will and signed consent form which approved by Chonbuk National University Hospital Institutional Review Board(IRB).

Exclusion criteria

Exclusion Criteria:

  • Subjects who have a history of blood, kidneys, endocrine, respiratory, gastrointestinal, urinary, cardiovascular, hepatic, psychiatric, neurological or allergic diseases that is (Except untreated asymptomatic seasonal allergies at the time of administration)
  • Subjects who have a history of gastrointestinal disease or gastrointestinal surgery which can affect drug absorption.
  • Subjects who drink Alcohol > 210g/week within 6 months prior to the screening.
  • Subjects who involved in other clinical trials within two months before the first dose medication characters.
  • Subjects who show Systolic Blood Pressure ≤100 or ≥150 mmHg or Diastolic Blood Pressure ≤60 or ≥100 mmHg at screening
  • Subjects who had alcohol or drug abuse within one year before the screening
  • Subjects who took medication of drug-metabolizing enzymes that are known to significantly induce or inhibit within 30 days
  • Subjects who smoke 20 cigarettes or more a day
  • Subjects who take medicine within 10 days before the first product administration.
  • Subject who done the whole blood donation within two months or component blood donation within 1 month within 1 month prior to the first dosing.
  • Subject who can increase risk due to clinical test and administration of drugs or has severe grade / chronic medical, mental condition or abnormal laboratory result that may interfere with the analysis of test results.
  • Subjects with serious history of or allergy to investigational product.
  • Subjects with severe hepatic impairment or Gallbladder Disease.
  • Subject with hereditary angioedema or a history of angioedema when treated with ACE(Angiotensin-Converting enzyme) inhibitor or ARB(Angiotensin II Receptor Blocker) therapy
  • Subjects who take combination medication with aliskiren in Diabetic patient or moderate to severe renal insufficient subjects (\<60mL/min/1.73m2)
  • Subjects with severe hepatic impairment
  • Subjects who have severe aortic stenosis
  • Subjects with acute or severe renal failure
  • Subjects with hyponatremia or hypokalemia
  • Subjects with Addison's disease
  • Subjects with hypercalcemia
  • Subjects who have galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
  • Subjects who are unwilling or unable to comply with the Lifestyle guidelines described in this protocol
  • Subject who are inadequate for this study to participate judged by investigator
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Active comparator
    Telmisartan, Amlodipine

    Drug: Telmisartan 80mg · Drug: Amlodipine10mg

  • Active comparator
    Hydrochlorothiazide

    Drug: Hydrochlorothiazide

  • Experimental
    Telmisartan, Amlodipine, Hydrochlorothiazide

    Drug: Telmisartan 80mg · Drug: Amlodipine10mg · Drug: Hydrochlorothiazide

Interventions

06

What researchers measure

Primary outcomes

  1. AUClast

    Time frame: Hour 0 (Pre-dose), Hour 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144(Total 19 points)]

  2. Cmax

    Time frame: Hour 0 (Pre-dose), Hour 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144(Total 19 points)]

Secondary outcomes

  1. AUCinf

    Time frame: Hour 0 (Pre-dose), Hour 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144(Total 19 points)]

  2. Tmax

    Time frame: Hour 0 (Pre-dose), Hour 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144(Total 19 points)]

Other outcomes

  1. t1/2

    Time frame: Hour 0 (Pre-dose), Hour 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144(Total 19 points)]

  2. CL/F

    Time frame: Hour 0 (Pre-dose), Hour 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144(Total 19 points)]

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Moon SJ, Jeon JY, Yu KS, Kim MG. Pharmacokinetic Interaction Among Telmisartan, Amlodipine, and Hydrochlorothiazide After a Single Oral Administration in Healthy Male Subjects. Clin Ther. 2019 Nov;41(11):2273-2282. doi: 10.1016/j.clinthera.2019.08.020. Epub 2019 Sep 26. PubMed 31564513 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2013 to primary completion in Feb 2014, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2019
First posted
Mar 26, 2019
StartActual
Dec 19, 2013
Primary completionActual
Feb 19, 2014
CompletionActual
Feb 19, 2014
Last update
Mar 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03889145
Responsible party
Sponsor
First posted
Mar 26, 2019
Start date
Dec 19, 2013
Primary completion
Feb 19, 2014
Completion
Feb 19, 2014
Last update
Mar 26, 2019

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Telmisartan · Hydrochlorothiazide

Start the discussion